In vitro killing of neuroblastoma cells by neutrophils derived from granulocyte colony-stimulating factor-treated cancer patients using an anti-disialoganglioside/anti-Fc gamma RI bispecific antibody.
Neutrophils isolated from cancer patients treated with granulocyte colony-stimulating factor (G-CSF) express high levels of Fc gamma RI. They exhibited an efficient killing of GD2+ neuroblastoma cells in the presence of an antidisialoganglioside (GD2) mouse monoclonal antibody (MoAb; 7A4, IgG3 kappa). However, this cytotoxicity was totally blocked by human monomeric IgG. In contrast, a bispecific antibody (7A4 bis 22/MDX-260), prepared by chemically linking an F(ab') fragment of 7A4 with an F(ab') fragment of an anti-Fc gamma RI MoAb, 22, which binds outside the Fc binding domain, triggered antibody-dependent cell cytotoxicity, even when neutrophils were preincubated with human monomeric IgG. F(ab')2 22 MoAb abrogated the MDX-260 killing without affecting that of 7A4. The 3G8 MoAb, directed against the Fc gamma RIII binding site, did not inhibit the cytotoxicity induced by either antibody. Thus, these results indicate that G-CSF-activated neutrophils exert their cytotoxic effect against neuroblastoma cells through Fc gamma RI and not Fc gamma RIII, and that the saturation of the high affinity Fc gamma RI by monomeric IgG can be overcome by the use of bispecific antibodies binding epitopes outside the IgG Fc gamma RI binding site. A combined administration of such bispecific antibodies and G-CSF may be, therefore, an efficient therapeutic approach to trigger tumor lysis by cytotoxic neutrophils in vivo.
Michon
J
J
INSERM Unité 255, Institut Curie, Paris, France.
Moutel
S
S
Barbet
J
J
Romet-Lemonne
J L
JL
Deo
Y M
YM
Fridman
W H
WH
Teillaud
J L
JL
D018033:Antibodies, Bispecific / Q000276:immunology*; D000920:Antibody-Dependent Cell Cytotoxicity; D005732:Gangliosides / Q000276:immunology*; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D007111:Immunity, Cellular; D000922:Immunotoxins; D066298:In Vitro Techniques; D009447:Neuroblastoma / Q000473:pathology* / Q000628:therapy; D009504:Neutrophils / Q000276:immunology*; D011961:Receptors, Fc / Q000276:immunology*
D018033:Antibodies, Bispecific; D005732:Gangliosides; D000922:Immunotoxins; D011961:Receptors, Fc; C025447:sialogangliosides; D016179:Granulocyte Colony-Stimulating Factor